We appreciate the comments of Fowler et al. In their letter, they compared the maximal maternal inhalation level of polycyclic aromatic hydro carbons (PAHs) in Krakow, Poland ([@b2-ehp-117-a140a]), with the mean fetal liver dose in Aberdeen, United Kingdom ([@b3-ehp-117-a140a]). The goal of this comparison seems to have been to examine whether the fetal exposure concentration following transplacental transfer of the PAHs is higher than the airborne concentration for the mother. This is an important question because in epidemiologic investigations of developmental and health consequences of prenatal PAH exposure, researchers often assume comparability in maternal exposure level and fetal exposure dose. Fowler et al. propose two inferences in their comments: *a*) the fetal liver exposure concentration resulting from transplacental transfer of the PAHs is higher than the maternal exposure concentration of airborne PAHs; and *b*) the relative proportion of individual PAHs for the fetal liver might be different from those experienced by the mothers. However, the two studies differ in several important aspects. Direct fetal--maternal comparison based on combining the data from the two studies as proposed by Fowler et al. is problematic for the following reasons.

First, in our study ([@b2-ehp-117-a140a]) we targeted nonsmoking pregnant women with no known risks of adverse birth outcomes in Krakow, Poland. To preclude the possibility of confounding by heavy environmental tobacco smoke (ETS) exposure or unreported maternal cigarette smoking, we further restricted the mother--newborn pairs to those with umbilical cord cotinine concentrations \< 25 ng/mL in our analysis of the birth outcomes. Within our Polish cohort, mean (± SD) newborn and maternal plasma cotinine levels were 0.32 ± 0.88 and 0.28 ± 0.24 ng/mL, respectively ([@b1-ehp-117-a140a]). Fetal cotinine levels reported by [@b3-ehp-117-a140a] for the smoking mothers (45.2 ± 2.5 ng/mL, mean ± SE) were about 75-fold higher than those for the nonsmoking mothers (0.6 ± 1.9 ng/mL). In contrast, the fetal liver concentrations of benz\[*a*\]anthracene, benzo\[*ghi*\] perylene, benzo\[*a*\]pyrene (BaP), chrysene, dibenzo\[*a,h*\]anthracene, and indeno\[1,2,\--*cd*\]pyrene for the smoking mothers are lower than those of the nonsmoking mothers by to 18--75% \[Table 3 of [@b3-ehp-117-a140a]\]. Lack of correlation between cotinine and PAH levels in the nonsmoking women raise doubt about the appropriateness of the compari son based on their control group.

Second, major sources of the PAHs in Krakow were coal- and diesel-combustion ([@b2-ehp-117-a140a]). In contrast, the relative proportions of the fetal liver PAHs from the smoking and the nonsmoking women reported by [@b3-ehp-117-a140a] are almost identical. This suggests that major sources of PAHs in this study are maternal smoking or intensive ETS exposure. In their letter, Fowler et al. observed that the relative proportion of the maternal airborne exposure (from our study) is very different from the similar proportions in the fetal liver. They interpret this as very different proportions of PAHs accumulating in the liver following the maternal inhalation. However, we suspect that the difference in relative proportions of maternal air and fetal liver PAHs is likely due to the differences in the sources of the PAHs between the two studies, as well as to differential accumulation.

Third, it is unknown whether the demographic and socioeconomic characteristics of the maternal cohorts of the two studies are similar enough to support the comparison of the maternal airborne concentration with the fetal liver level. The maternal cohort of [@b3-ehp-117-a140a] elected medical abortion; about half of these women smoked intensively during their pregnancy. In contrast, the women in our cohort ([@b2-ehp-117-a140a]) successfully carried their pregnancies and were more likely to engage in healthy behaviors. Therefore, residual confounding by the maternal behaviors (such as micro nutrient intake during pregnancy), socioeconomic status, and genetic polymorphisms might have further contributed to the differences in maternal air and fetal liver dose.

A substantial body of evidence suggests that fetuses are much more susceptible to PAH-induced carcinogenesis than are adults ([@b6-ehp-117-a140a]; [@b7-ehp-117-a140a]), despite the likelihood that the transplacental dose of PAHs to the fetus is at least an order of magnitude lower than the maternal tissue levels ([@b4-ehp-117-a140a]; [@b8-ehp-117-a140a]). [@b5-ehp-117-a140a] reported that fetal PAH--DNA adduct levels were generally similar to those in the mothers; among ETS exposed mother--newborn pairs, the mean (± SD) maternal BaP--DNA adduct level was 0.23 ± 0.16 per 10^8^ nucleotides, and the fetal level was 0.24 ± 0.15 per 10^8^ nucleotides. Among the non-ETS exposed pairs, the mean maternal BaP--DNA adduct level was 0.21 ± 0.12 per 10^8^ nucleotides, and the fetal level was 0.24 ± 0.15 per 10^8^ nucleotides ([@b5-ehp-117-a140a]).

The issue raised by Fowler et al. in their letter is important because little is known about the actual concentration or type of PAHs that reach the fetus following maternal inhalation. Determining the actual fetal tissue dose is critical in understanding the sources of fetal vulnerability as well as the health effects of their exposure. However, the lack of comparability in maternal populations of the two studies does not allow valid estimation of the magnitude of maternal--fetal level difference. We believe the concentration of fetal tissue accumulation in humans following maternal inhalation of the PAHs needs further investigation.
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